Mar 16 |
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
|
Mar 14 |
Kezar Life Sciences GAAP EPS of -$0.44
|
Mar 14 |
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
|
Mar 8 |
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
|
Feb 28 |
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
|
Feb 26 |
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
|
Feb 2 |
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
|
Nov 21 |
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
|
Nov 14 |
Kezar Life Sciences GAAP EPS of -$0.32 beats by $0.04, revenue of $7M beats by $6.7M
|
Nov 13 |
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|